{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:11:19Z","timestamp":1778695879285,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31071989"],"award-info":[{"award-number":["31071989"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12944-017-0406-9","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T08:41:29Z","timestamp":1484296889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Biochemical mechanism underlying hypertriglyceridemia and hepatic steatosis\/hepatomegaly induced by acute schisandrin B treatment in mice"],"prefix":"10.1186","volume":"16","author":[{"given":"Yi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Feng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Ling","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu-Sheng","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Yuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kam-Ming","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,13]]},"reference":[{"key":"406_CR1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ecl.2004.03.005","volume":"33","author":"AJ Cameron","year":"2004","unstructured":"Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004;33:351\u201375.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"406_CR2","doi-asserted-by":"crossref","unstructured":"Carpentier AC. Hypertriglyceridemia associated with abdominal obesity: getting contributing factors into perspective. Arterioscler Thromb Vasc Biol. 2015;35:2076\u20138.","DOI":"10.1161\/ATVBAHA.115.306412"},{"key":"406_CR3","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/pgmj.2010.204990rep","volume":"87","author":"GF Watts","year":"2011","unstructured":"Watts GF, Karpe F. Republished review: Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Postgrad Med J. 2011;87:776\u201382.","journal-title":"Postgrad Med J"},{"key":"406_CR4","doi-asserted-by":"crossref","unstructured":"Subramanian S, Chait A. Hypertriglyceridemia secondary to obesity and diabetes. Biochim Biophys Acta. 2012;1821:819\u201325.","DOI":"10.1016\/j.bbalip.2011.10.003"},{"key":"406_CR5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijsu.2015.08.080","volume":"25","author":"A Charlesworth","year":"2015","unstructured":"Charlesworth A, Steger A, Crook MA. Acute pancreatitis associated with severe hypertriglyceridaemia; A retrospective cohort study. Int J Surg. 2015;25:23\u20137.","journal-title":"Int J Surg"},{"key":"406_CR6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1902\/jop.2012.110756","volume":"84","author":"A Sangwan","year":"2013","unstructured":"Sangwan A, Tewari S, Singh H, Sharma RK, Narula SC. Periodontal status and hyperlipidemia: statin users versus non-users. J Periodontol. 2013;84:3\u201312.","journal-title":"J Periodontol"},{"key":"406_CR7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.genhosppsych.2012.02.004","volume":"34","author":"JH Hsu","year":"2012","unstructured":"Hsu JH, Chien IC, Lin CH, Chou YJ, Chou P. Hyperlipidemia in patients with schizophrenia: national population-based study. Gen Hosp Psychiatry. 2012;34:360\u20137.","journal-title":"Gen Hosp Psychiatry"},{"key":"406_CR8","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","volume":"1","author":"GC Farrell","year":"2006","unstructured":"Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;1:S99\u2013S112.","journal-title":"Hepatology"},{"key":"406_CR9","doi-asserted-by":"crossref","unstructured":"Loria P, Marchesini G, Nascimbeni F, Ballestri S, Maurantonio M, Carubbi F, et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis. 2014;232:99\u2013109.","DOI":"10.1016\/j.atherosclerosis.2013.10.030"},{"key":"406_CR10","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.bbalip.2011.11.010","volume":"21","author":"HC Hassing","year":"2012","unstructured":"Hassing HC, Surendran RP, Mooij HL, Stroes ES, Nieuwdorp M, Dallinga-Thie GM. Pathophysiology of hypertriglyceridemia. Biochim Biophys Acta. 2012;21:826\u201332.","journal-title":"Biochim Biophys Acta"},{"key":"406_CR11","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.freeradbiomed.2012.08.006","volume":"53","author":"R Checker","year":"2012","unstructured":"Checker R, Patwardhan RS, Sharma D, Menon J, Thoh M, Bhilwade HN, et al. Schisandrin B exhibits anti-inflammatory activity through modulation of the redox-sensitive transcription factors Nrf2 and NF-\u03baB. Free Radic Biol Med. 2012;53:1421\u201330.","journal-title":"Free Radic Biol Med"},{"key":"406_CR12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejphar.2012.05.030","volume":"692","author":"KW Zeng","year":"2012","unstructured":"Zeng KW, Zhang T, Fu H, Liu GX, Wang XM. Schisandrin B exerts anti-neuroinflammatory activity by inhibiting the Toll-like receptor 4-dependent MyD88\/IKK\/NF-\u03baB signaling pathway in lipopolysaccharide-induced microglia. Eur J Pharmacol. 2012;692:29\u201337.","journal-title":"Eur J Pharmacol"},{"key":"406_CR13","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1158\/1078-0432.CCR-07-1579","volume":"13","author":"L Li","year":"2007","unstructured":"Li L, Pan Q, Han W, Liu Z, Li L, Hu X. Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling. Clin Cancer Res. 2007;13:6753\u201360.","journal-title":"Clin Cancer Res"},{"key":"406_CR14","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1111\/j.1745-7254.2007.00614.x","volume":"28","author":"PY Chiu","year":"2007","unstructured":"Chiu PY, Leung HY, Siu AH, Poon MK, Ko KM. Schisandrin B decreases the sensitivity of mitochondria to calcium ion-induced permeability transition and protects against ischemia-reperfusion injury in rat hearts. Acta Pharmacol Sin. 2007;28:1559\u201365.","journal-title":"Acta Pharmacol Sin"},{"key":"406_CR15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1055\/s-2006-958123","volume":"61","author":"SP Ip","year":"1995","unstructured":"Ip SP, Poon MK, Wu SS, Che CT, Ng KH, Kong YC, et al. Effect of schisandrin B on hepatic glutathione antioxidant system in mice: protection against carbon tetrachloridetoxicity. Planta Med. 1995;61:398\u2013401.","journal-title":"Planta Med"},{"key":"406_CR16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1379\/1466-1268(2001)006<0044:EOSBPO>2.0.CO;2","volume":"6","author":"SP Ip","year":"2001","unstructured":"Ip SP, Che CT, Kong YC, Ko KM. Effects of schisandrin B pretreatment on tumor necrosis factor-\u03b1 induced apoptosis and Hsp 70 expression in mouse liver. Cell Stress Chaperones. 2001;6:44\u20138.","journal-title":"Cell Stress Chaperones"},{"key":"406_CR17","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bcp.2005.11.026","volume":"71","author":"L Li","year":"2006","unstructured":"Li L, Lu Q, Shen Y, Hu X. Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells. Biochem Pharmacol. 2006;71:584\u201395.","journal-title":"Biochem Pharmacol"},{"key":"406_CR18","doi-asserted-by":"crossref","unstructured":"Xu Y, Liu Z, Sun J, Pan Q, Sun F, Yan Z, et al. Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo. PLoS One. 2011;6:e28335.","DOI":"10.1371\/journal.pone.0028335"},{"key":"406_CR19","first-page":"1429","volume":"8","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Pan SY, Zhou SF, Wang XY, Sun N, Zhu PL, et al. Time and dose relationships between schisandrin B- and Schisandrae fructus oil-induced hepatotoxicity and the associated elevations in hepatic and serum triglyceride levels in mice. Drug Des Devel Ther. 2014;8:1429\u201339.","journal-title":"Drug Des Devel Ther"},{"key":"406_CR20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1254\/jphs.13087FP","volume":"123","author":"SY Pan","year":"2013","unstructured":"Pan SY, Jia ZH, Zhang Y, Yu Q, Wang XY, Sun N, et al. Novel mouse model of combined hyperlipidemia associated with steatosis and liver injury by a single-dose intragastric administration of schisandrin B\/cholesterol\/bile salts mixture. J Pharmacol Sci. 2013;123:110\u20139.","journal-title":"J Pharmacol Sci"},{"key":"406_CR21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejphar.2006.03.001","volume":"537","author":"SY Pan","year":"2006","unstructured":"Pan SY, Dong H, Han YF, Li WY, Zhao XY, Ko KM. A novel experimental model of acute hypertriglyceridemia induced by schisandrin B. Eur J Pharmacol. 2006;537:200\u20134.","journal-title":"Eur J Pharmacol"},{"key":"406_CR22","doi-asserted-by":"crossref","unstructured":"Lambert JE, Parks EJ. Postprandial metabolism of meal triglyceride in humans. Biochim Biophys Acta. 2012;1821:721\u20136.","DOI":"10.1016\/j.bbalip.2012.01.006"},{"key":"406_CR23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0009-8981(79)90182-7","volume":"94","author":"Z Reiner","year":"1979","unstructured":"Reiner Z, Koren E. Triglyceride-poor very low density lipoprotein in human serum. Clin Chim Acta. 1979;94:23\u20139.","journal-title":"Clin Chim Acta"},{"key":"406_CR24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cccn.2004.08.008","volume":"351","author":"M Kinoshita","year":"2005","unstructured":"Kinoshita M, Kojima M, Matsushima T, Teramoto T. Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin Chim Acta. 2005;351:115\u201320.","journal-title":"Clin Chim Acta"},{"key":"406_CR25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0167-7306(08)60517-7","volume":"31","author":"DA Bernlohr","year":"1996","unstructured":"Bernlohr DA, Simpson MA. Adipose tissue and lipid metabolism. New Comprehensive Biochemistry. 1996;31:257\u2013381.","journal-title":"New Comprehensive Biochemistry"},{"key":"406_CR26","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.3390\/ijms15046184","volume":"15","author":"UJ Jung","year":"2014","unstructured":"Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15:6184\u2013223.","journal-title":"Int J Mol Sci"},{"key":"406_CR27","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/hep.21788","volume":"45","author":"CJ McClain","year":"2007","unstructured":"McClain CJ, Barve S, Deaciuc I. Good fat\/bad fat. Hepatology. 2007;45:1343\u20136.","journal-title":"Hepatology"},{"key":"406_CR28","doi-asserted-by":"crossref","unstructured":"Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Lonardo A. The Role ofNuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. Adv Ther. 2016;33:291\u2013319.","DOI":"10.1007\/s12325-016-0306-9"},{"key":"406_CR29","doi-asserted-by":"crossref","unstructured":"Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. 2015;47:997\u20131006.","DOI":"10.1016\/j.dld.2015.08.004"},{"key":"406_CR30","doi-asserted-by":"crossref","unstructured":"Pan SY, Dong H, Guo BF, Zhang Y, Yu ZL, Fong WF, et al. Effective kinetics of schisandrin B on serum\/hepatic triglyceride and total cholesterol levels in mice with and without the influence of fenofibrate. Naunyn Schmiedebergs Arch Pharmacol. 2011;383:585\u201391.","DOI":"10.1007\/s00210-011-0634-x"},{"key":"406_CR31","doi-asserted-by":"crossref","first-page":"G762","DOI":"10.1152\/ajpgi.00476.2011","volume":"302","author":"JL Trevaskis","year":"2012","unstructured":"Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol. 2012;302:G762\u201372.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"406_CR32","first-page":"2001","volume":"9","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Zhou ZW, Jin H, Hu C, He ZX, Yu ZL, et al. Schisandrin B inhibits cell growth and induces cellular apoptosis and autophagy in mouse hepatocytes and macrophages: implications for its hepatotoxicity. Drug Des Devel Ther. 2015;9:2001\u201327.","journal-title":"Drug Des Devel Ther"},{"key":"406_CR33","doi-asserted-by":"crossref","unstructured":"Gu Q, Yang X, Lin L, Li S, Li Q, Zhong S, et al. Genetic ablation of solute carrier family 7a3a leads to hepatic steatosis in zebrafish during fasting. Hepatology. 2014;60:1929\u201341.","DOI":"10.1002\/hep.27356"},{"key":"406_CR34","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1172\/JCI115207","volume":"87","author":"AJ Strain","year":"1991","unstructured":"Strain AJ, Ismail T, Tsubouchi H, Arakaki N, Hishida T, Kitamura N, et al. Native and recombinant human hepatocyte growth factors are highly potent promoters of DNA synthesis in both human and rat hepatocytes. J Clin Invest. 1991;87:1853\u20137.","journal-title":"J Clin Invest"},{"key":"406_CR35","doi-asserted-by":"crossref","first-page":"G204","DOI":"10.1152\/ajpgi.00021.2007","volume":"293","author":"T Kosone","year":"2007","unstructured":"Kosone T, Takagi H, Horiguchi N, Ariyama Y, Otsuka T, Sohara N, et al. HGF ameliorates a high fat diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol. 2007;293:G204\u201310.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"406_CR36","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/hep.20179","volume":"39","author":"MJ Walsh","year":"2004","unstructured":"Walsh MJ, Vanags DM, Clouston AD, Richardson MM, Purdie DM, Jonsson JR, et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology. 2004;39:1230\u20138.","journal-title":"Hepatology"},{"key":"406_CR37","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jhep.2011.09.020","volume":"56","author":"B Sun","year":"2012","unstructured":"Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatology. 2012;56:704\u201313.","journal-title":"J Hepatology"},{"key":"406_CR38","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.3748\/wjg.v12.i46.7413","volume":"12","author":"G Kolios","year":"2006","unstructured":"Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol. 2006;12:7413\u201320.","journal-title":"World J Gastroenterol"},{"key":"406_CR39","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cld.2004.04.009","volume":"8","author":"SH Caldwell","year":"2004","unstructured":"Caldwell SH, Chang CY, Nakamoto RK, Krugner-Higby L. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:595\u2013617.","journal-title":"Clin Liver Dis"},{"key":"406_CR40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3748\/wjg.14.193","volume":"14","author":"Y Wei","year":"2008","unstructured":"Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol. 2008;14:193\u20139.","journal-title":"World J Gastroenterol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-017-0406-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T04:11:55Z","timestamp":1498363915000},"score":1,"resource":{"primary":{"URL":"http:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-017-0406-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,13]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["406"],"URL":"https:\/\/doi.org\/10.1186\/s12944-017-0406-9","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,13]]},"article-number":"8"}}